| Lutetium (177lu) Vipivotide Tetraxetan studied in …STUDIED_INderived43 of 43show fewer |
|---|
| → studied in | NCT06095089Phase 1 · recruiting A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer · 43 trials list this drug (30 active) | — | — | Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05818683Phase 1 · recruiting A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer · 43 trials list this drug (30 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07650240Phase 2 · recruiting Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial · 43 trials list this drug (30 active) | — | — | Prostate Adenocarcinoma,Malignant Prostate Neoplasm,Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03042468Phase 1/Phase 2 · completed Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC · 43 trials list this drug (30 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04689828Phase 3 · active not recruiting 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer · 43 trials list this drug (30 active) | — | — | Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05766371Phase 2 · recruiting Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer · 43 trials list this drug (30 active) | — | — | Prostate Neoplasm,Malignant Prostate Neoplasm,Prostate Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06632977Phase 2 · recruiting Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial · 43 trials list this drug (30 active) | — | — | Malignant Prostate Neoplasm,Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07200830Phase 3 · recruiting Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial · 43 trials list this drug (30 active) | — | — | Prostate Adenocarcinoma,Malignant Prostate Neoplasm,Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07698535Phase 2 · recruiting Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial · 43 trials list this drug (30 active) | — | — | Malignant Prostate Neoplasm,Castration-Resistant Prostate Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06200103Phase 2 · suspended Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer · 43 trials list this drug (30 active) | — | — | Malignant Prostate Neoplasm,Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06145633Phase 2 · recruiting Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer · 43 trials list this drug (30 active) | — | — | Prostate Adenocarcinoma,Malignant Prostate Neoplasm,Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06526299Phase 2 · recruiting Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease · 43 trials list this drug (30 active) | — | — | Malignant Prostate Neoplasm,Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07682649Phase 1 · not yet recruiting Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer · 43 trials list this drug (30 active) | — | — | Malignant Prostate Neoplasm,Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05079698Phase 1 · active not recruiting A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer · 43 trials list this drug (30 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06461689completed Comparison of Changes in Tumor Burden in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in Metastatic Castration-resistant Prostate Cancer · 43 trials list this drug (30 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04886986Phase 1 · recruiting Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer · 43 trials list this drug (30 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04720157Phase 3 · active not recruiting An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) · 43 trials list this drug (30 active) | — | — | Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06783348Phase 2 · recruiting Radiopharmaceutical Treatment of Advanced Kidney Cancer · 43 trials list this drug (30 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07223034Phase 1 · recruiting A Study of 177Lu-PSMA-617 in People With Gliomas · 43 trials list this drug (30 active) | — | — | Glioma,Glioblastoma, IDH-Wildtype,Diffuse Astrocytoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07145177Phase 1 · recruiting 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer · 43 trials list this drug (30 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05682443Phase 1/Phase 2 · active not recruiting ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC · 43 trials list this drug (30 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07025512Phase 2 · withdrawn 177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia · 43 trials list this drug (30 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07219147Phase 1 · recruiting 177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer · 43 trials list this drug (30 active) | — | — | Malignant Prostate Neoplasm,Castration-Resistant Prostate Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06303713Phase 1 · active not recruiting LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer · 43 trials list this drug (30 active) | — | — | Malignant Prostate Neoplasm,Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04663997Phase 2 · active not recruiting 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer · 43 trials list this drug (30 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06288113Phase 2 · recruiting Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial · 43 trials list this drug (30 active) | — | — | Malignant Prostate Neoplasm,Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06216249Phase 2 · recruiting Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT) · 43 trials list this drug (30 active) | — | — | Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04443062Phase 2 · completed Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer · 43 trials list this drug (30 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06964958Phase 2 · active not recruiting 177LuPSMA in Renal Cell Carcinoma · 43 trials list this drug (30 active) | — | — | Malignant Kidney Neoplasm,Clear Cell Renal Cell Carcinoma,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06084338Phase 2 · recruiting Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc · 43 trials list this drug (30 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05162573Phase 1 · completed EBRT + Lu-PSMA for N1M0 Prostate Cancer · 43 trials list this drug (30 active) | — | — | Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06943495Phase 1 · recruiting Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2) · 43 trials list this drug (30 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04343885Phase 2 · active not recruiting In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy · 43 trials list this drug (30 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05340374Phase 1/Phase 2 · active not recruiting Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer · 43 trials list this drug (30 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06199453Phase 2 · withdrawn The Evaluation of the Effectiveness, Safety and Tolerability of Treatment, Using a PSMA-Lu177, in Patients with ACC- an Open, Non-commercial Clinical Trial · 43 trials list this drug (30 active) | — | — | Adenoid Cystic Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06449781Phase 2 · recruiting 177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer · 43 trials list this drug (30 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03511664Phase 3 · completed Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer · 43 trials list this drug (30 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04430192Phase 1/Phase 2 · active not recruiting Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy · 43 trials list this drug (30 active) | — | — | Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06329830Phase 1/Phase 2 · withdrawn 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer · 43 trials list this drug (30 active) | — | — | Malignant Prostate Neoplasm,Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05150236Phase 2 · unknown EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC · 43 trials list this drug (30 active) | — | — | Neoplasm,Neoplasm by Site,Prostate Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04825652no longer available 177Lu-PSMA-617 Managed Access Program for mCRPC Patients · 43 trials list this drug (30 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03545165Phase 1/Phase 2 · terminated 177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC · 43 trials list this drug (30 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03042312Phase 2 · terminated Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy · 43 trials list this drug (30 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |